Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Consensus seems to be around $3-4B *after* positive NASH results. This is also consistent with analyst targets, more or less.
Right now VKTX is being valued similarly to AKRO, which has a somewhat junky injectable that had okay results in a Phase 2 trial and has no other viable products.
If NASH is positive, oral GLP-1/GIP is positive, and the X-ALD program is also positive, who knows?
VKTX
Schedule of events
Apr 26 4:30 EST VKTX conference call
Q2: VK2809 P2B results
Q3: VK2735 P2 initiation
Q3: VK0214 X-ALD P1b results
Q4: VK2735 P1 oral results
Q4: VK0214 breakthrough therapy designation(?) (already orphan drug)
Is there anything the fine minds here can add to this in terms of other events (MDGL, other biotech companies, regulatory milestones, approvals, etc.) in any of VKTX's core competencies that might impact the company?
Unless they were the only ones not being webcasted they are wrong since every other company provided links to their webcasts
Thank you. Unfortunately that link goes directly to Amneal (as do all of the others from companies that were kind enough to post the actual link).
VKTX is often frustratingly stupid and amateurish. I am also confused about why they never publish or present their data.
Note that I am not accusing them of fraud or anything. It is just standard practice at *every* small biotech to have a well-oiled publication machine in place, complete with a scientific platform. I know they do not have the former, and suspect that they do not have the latter. Again, very amateur hour.
Anyone have a link to the live presentations at Needham?
The dipshits in VKTX's PR department neglected to include a registration link in their PR and I can't find it anywhere
VKTX hitting 52-week highs, likely driven by Twitter and increased NVO obesity sales data and a lot of hopium.
Oh boy am I having a year based on the names I have talked about here. Now I just need a miracle to happen with ARAV. I only have a trivial amount invested in it but would be nice.
I just want to be clear I'm not an RVNC bear nor do I have any interest in shorting it.
There was just some discussion about why the stock is down and I like arguing.
No harm no foul
ARAV
Just appointed a new and reasonably well paid COO to lead their launch in advance of their Phase 3 results which should be reported shortly.
If you work in biotech/pharma, you know that there are a number of days or a week elapses between when the data are available for a study and when you press release it simply because it is physically impossible to do an instant press release.
My guess here is that they have the data in hand and were confident enough to hire this person. They probably negotiated with her in advance and made the hire contingent on knowing whether they have a viable product.
Either that or the data are bad and the COO is going to be out of a job in 3 months LOL
Ha I have had *many* biotech failures over the years but I actually made a lot of money on RPRX (and also YMI if you remember that one)! I believe I lost more than half of my RPRX profits on JAV in like 6 months.
It was funny because I was sitting with my accountant as he was manually going through my brokerage statement and he was like "wow you made a ton in...oh no, oh no"
Well that was a day for VKTX
Any other recent examples of similar reactions to large offerings? I've lived through so many and this is quite unusual.
LOL the VKTX offering does not appear to be triggering a run for the exits
LOL quite a bit of enthusiasm for VKTX. I've made good money in biotech over the years but it is nice to be in the middle of the hottest biotech...ever? Anyone want to poke holes in VKTX? I think I'm overconfident.
"The truly astonishing part to this story, though, is that Viking's stock might still be incredibly undervalued. Here's a quick overview on why this sizzling growth stock may increase tenfold before year's end."
"The truly astonishing part to this story, though, is that Viking's stock might still be incredibly undervalued. Here's a quick overview on why this sizzling growth stock may increase tenfold before year's end."
"Who might be a suitor? Pfizer, Bristol Myers Squibb, and Gilead Sciences have all attempted to develop NASH drugs in the past with little to show for it. What's more, all three of these biopharma heavyweights have the financial firepower to acquire Viking with ease."
"Bottom line: Viking has a realistic pathway toward a $12 billion-plus valuation by the close of 2023, depending on the outcomes of VK2809 in NASH, VK2735 in obesity, and interest from possible suitors."
https://www.fool.com/investing/2023/03/29/up-463-this-sizzling-growth-stock-could-have-a-lot/
Well I just dropped some more potentially ill-advised dollars in ARAV
Batrixacept is their only product; it has to be used in combo with other agents where it may restore sensitivity to those agents. Phase 3 data in breast in combo with paclitaxel relatively shortly and BLA in 4Q23 if successful. Also earlier trials for ccRCC and pancreatic, data in the next quarter or so.
Dew I tried to get out of biotech and you sucked me back in
VKTX
Well I haven't looked at the data in detail yet but it appears that VKTX's VK2735 blew away other agents in the class
Yesterday's fall in VKTX was literally the most idiotic and irrational thing I've ever seen in 20+ years of working in biotech.
Shares of Viking Therapeutics (VKTX) trading down on concerns stemming from Altimmune's (ALT) "underwhelming" date this morning, William Blair the analyst tells investors in a research note. The analyst emphasizes that Viking's VK2735 is a dual GLP-1/GIP agonist on track to have first-in-human data in obese individuals later this morning or in April. In contrast, Altimmune's pemvidutide is a dual GLP-1/glucagon receptor agonist with a different mechanism of action, and therefore has limited read-through to Viking. In addition, Blair says the bullish thesis on Viking remains on its non-alcoholic steatohepatitis asset, VK2809. It is a buyer of the stock on the selloff and keeps an Outperform rating on the name.